Can raloxifene and denosumab (Prolia) be used together for osteoporosis treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Raloxifene and Prolia Be Used Together?

Raloxifene and denosumab (Prolia) should not be used together as concurrent combination therapy for osteoporosis, but raloxifene can be used sequentially after denosumab discontinuation, though it is significantly inferior to bisphosphonates for preventing the dangerous rebound effect.

The Critical Context: Denosumab Discontinuation

The key issue here is understanding that these medications serve different roles in osteoporosis management. Denosumab should never be stopped without immediate follow-up antiresorptive therapy because discontinuation triggers a severe rebound effect characterized by:

  • Rapid spike in bone turnover markers
  • Accelerated bone loss
  • Up to 20% risk of multiple spontaneous vertebral fractures 1, 2

Why Not Use Them Together?

Current guidelines position these as alternative monotherapy options, not combination treatments:

  • Denosumab is recommended as first-line therapy for high fracture risk patients 1
  • Raloxifene is reserved for specific scenarios: patients with low DVT risk where bisphosphonates/denosumab are inappropriate, or those with high breast cancer risk 1

The 2023 American College of Physicians guideline found insufficient evidence to recommend raloxifene for osteoporosis treatment, noting it only reduces vertebral (not hip) fractures 3.

Sequential Use: Raloxifene After Denosumab (Not Recommended)

While technically possible to use raloxifene after stopping denosumab, this approach is clinically inadequate and potentially dangerous:

The Evidence Against Raloxifene Post-Denosumab:

The CARD study 4 directly compared raloxifene versus alendronate after 12 months of denosumab:

  • Raloxifene failed to maintain bone turnover suppression (markers returned to baseline)
  • Spine BMD decreased 2.0% (P=0.003)
  • Total hip BMD decreased 1.2% (P=0.008)
  • Alendronate maintained all BMD gains and kept turnover markers suppressed

A 2018 case report 5 documented complete failure: A patient given raloxifene after denosumab discontinuation experienced high bone turnover and spontaneous clinical vertebral fractures despite treatment.

The Correct Approach After Denosumab

When discontinuing denosumab, use potent bisphosphonates (alendronate or zoledronic acid), NOT raloxifene 1, 6, 4:

  • Alendronate 70 mg weekly for at least 12 months effectively prevents rebound 6, 4
  • High-dose potent bisphosphonates are needed to maintain bone turnover in the low premenopausal range 2
  • The 2019 Endocrine Society guideline explicitly states: "subsequent antiresorptive [e.g., bisphosphonates, hormone therapy, or selective estrogen receptor modulators]" but the evidence strongly favors bisphosphonates 1

Clinical Algorithm

If patient is currently on denosumab:

  • Continue denosumab on schedule (every 6 months) OR
  • Transition to alendronate or zoledronic acid (never stop without replacement)

If considering raloxifene:

  • Use only as initial monotherapy in patients who:
    • Have low DVT/stroke risk
    • Cannot take bisphosphonates or denosumab
    • Have high breast cancer risk
    • Accept that it only prevents vertebral fractures 1

Never use raloxifene after denosumab discontinuation given the high-quality evidence showing inadequate protection against rebound fractures 5, 4.

Key Pitfalls to Avoid

  • Do not delay or interrupt denosumab without immediate antiresorptive replacement—the rebound effect begins within 6 months 1
  • Do not assume all antiresorptives are equivalent post-denosumab—raloxifene is demonstrably inferior to bisphosphonates 4
  • Do not use raloxifene if the patient has any DVT/stroke risk factors—it significantly increases these risks 1

Drug Interaction Profile

The FDA label for raloxifene 7 does not list denosumab as a contraindicated combination, but this reflects lack of studied concurrent use rather than safety approval. No pharmacokinetic interactions are expected, but the clinical question is about therapeutic appropriateness, not drug-drug interactions.

References

Research

The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2024

Research

One versus 2 years of alendronate following denosumab: the CARD extension.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.